The Patent Finder
GE

Genoa Corporation

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesPatent listSources & methods

0 patents currently held, every record listed here

5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.

This portfolio holds none of the 5 US patents in force on its record. from the record

Of the 5 now held by other companies, 5 name Avalyn Pharma Inc. as their current owner. Each row says so.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
none
Next term end

When these terms end

Each bar runs from grant to computed term end. 2017 to 2035.
US 11,224,592 Aerosol Pirfenidone and Pyridone Analog Compounds and Uses Thereof Jan 31, 2032
US 10,092,552 Aerosol Pirfenidone and Pyridone Analog Compounds and Uses Thereof Apr 24, 2032
US 10,105,356 Aerosol Pirfenidone and Pyridone Analog Compounds and Uses Thereof Apr 24, 2032
US 9,770,443 Aerosol Pirfenidone and Pyridone Analog Compounds and Uses Thereof Jan 9, 2035
US 10,028,966 Aerosol Pirfenidone and Pyridone Analog Compounds and Uses Thereof Jan 9, 2035
20212025202920332035
1 pending application: term is not computable until grant.Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
None of the currently held patents qualifies as notable.

Formerly held, still cited

Notable
The most cited patent in this portfolio, cited by 52 later US patents, top 5% of utility patents granted in 2018 in our data. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
now held by Avalyn Pharma Inc.
Ends Apr 2032 · High confidence
Also notable
Cited by 25 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
now held by Avalyn Pharma Inc.
Ends Jan 2035 · High confidence

Fee deadlines

No maintenance fee falls due on this company's record before Nov 10, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first.
Also on record: 5 patents in force now held by others · 20 patents ended · 1 application pending · 2 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
6 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited